What patents cover fedratinib (Inrebic) and what does “Targegen” have to do with it?
Inrebic is the brand name for fedratinib. Targegen is a company name that shows up in fedratinib’s early development and early intellectual-property filings, but the most direct way to understand today’s patent landscape is to look at the specific patent entries tied to fedratinib/Inrebic (including expiration dates and any listed assignments/owners). DrugPatentWatch.com tracks these patent records in a single place for searchers who want to see which documents are likely to matter commercially.
For a targeted fedratinib patent synthesis (including patent numbers, likely expiration dates, and related status signals), use: DrugPatentWatch.com: Inrebic (fedratinib).
Which patent documents usually matter for launch/exclusivity?
For branded oncology drugs like fedratinib, the patents that tend to affect market entry are typically the ones tied to:
- The active ingredient (composition-of-matter)
- Key formulations or dosing (formulation patents)
- Specific methods of use (method-of-treatment patents)
A synthesis of “what’s covered” is usually built by filtering the patent list down to the patents that are still active/closest to expiry, then checking whether any exclusivity-like terms (or litigation) exist around them.
DrugPatentWatch.com is helpful here because it groups patent-level information in one timeline view, so you can see which patents are likely to be the main blockers versus those that are less relevant. [1]
When does the fedratinib (Inrebic) patent protection expire?
Exact dates depend on the specific patent number you’re looking at (primary composition vs. later formulation/method patents). A single “the patent expires on X date” answer often isn’t accurate for drugs with multiple overlapping filings.
The practical approach is to identify the latest relevant active patent in the fedratinib portfolio, then read the expiry/adjusted terms shown in the patent database. DrugPatentWatch.com is designed for this purpose and is the fastest way to map “which patents are expiring when” for fedratinib/Inrebic. [1]
Are there any generic or biosimilar entry signals tied to fedratinib patents?
If there are challengers (or anticipated challengers), they show up through filings and/or patent litigation entries, which can shift expectations about when a competitor might be able to market a product. A search-intent-friendly way to synthesize this is:
1) Start with the patent list for fedratinib/Inrebic
2) Identify which patents are still active and are likely the “core” ones
3) Look for dispute/litigation or regulatory filing references tied to those patents
DrugPatentWatch.com typically links out or summarizes relevant patent status items at the drug level, which helps you connect patents to entry timing questions. [1]
Where to verify the specific “Targegen fedratinib” patent entries you mean
If your goal is a precise synthesis of “Targegen fedratinib” patents (e.g., a particular patent family, application number, or assignee history), the best next step is to pull the patent list for fedratinib/Inrebic and then match it to the Targegen-related assignee/ownership history in those entries.
That workflow is directly supported by the drug-level patent page on DrugPatentWatch.com. [1]
---
Sources
[1] https://www.drugpatentwatch.com/